Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17579213 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Giraud J, et al. (2007) Phosphorylation of Irs1 at SER-522 inhibits insulin signaling. Mol Endocrinol 21, 2294-302 17579213
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (rat) ▲
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced decrease
PD98059 insulin no change compared to control
rapamycin insulin no change compared to control
glucose starvation no change compared to control
insulin glucose starvation increase

T203-p - ERK1 (rat) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
PD98059 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control
glucose starvation no change compared to control
insulin glucose starvation increase

Y205-p - ERK1 (rat) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation no change compared to control
insulin glucose starvation increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
PD98059 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control

T183-p - ERK2 (rat) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation no change compared to control
insulin glucose starvation increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
PD98059 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control

Y185-p - ERK2 (rat) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation no change compared to control
insulin glucose starvation increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
PD98059 insulin inhibit treatment-induced increase
rapamycin insulin no change compared to control

S302-p - IRS1 (rat) ▲
Orthologous residues
IRS1 (human): S307‑p, IRS1 (mouse): S302‑p, IRS1 (rat): S302‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat

S522-p - IRS1 (rat) ▲
Orthologous residues
IRS1 (human): S527‑p, IRS1 (mouse): S522‑p, IRS1 (rat): S522‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), CHO (fibroblast) [IRS1 (human)], L6 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (rat) siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced decrease
PD98059 insulin no change compared to control
rapamycin insulin no change compared to control
glucose starvation no change compared to control
insulin glucose starvation increase
siRNA, insulin inhibit treatment-induced increase Akt siRNA

T389-p - p70S6K iso2 (rat) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
PD98059 insulin inhibit treatment-induced decrease
rapamycin insulin inhibit treatment-induced increase
glucose starvation no change compared to control
insulin glucose starvation increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.